Flu deaths are never just a story about the worst cases, they reflect how fast influenza surges through hospitals and workplaces. During 2018 to 2019, about 800,000 U.S. flu associated respiratory hospitalizations were linked to circulating viruses, yet vaccine effectiveness can be only about one third against influenza B and still around 39% overall for one recent season. With hospitalization risk rising sharply, we can follow how circulating drift, coverage gaps, and symptom patterns reshape the path from infection to severe outcomes.
Key Takeaways
- 800,000 U.S. flu-associated respiratory hospitalizations occurred in 2018–2019, meaning about 800,000 respiratory hospitalizations were associated with influenza
- 30%–60% of circulating flu viruses during seasonal outbreaks are antigenically drifted variants, meaning vaccine-targeted strains may not fully match circulating viruses
- 2.5x higher risk of hospitalization among adults 50+ with influenza compared with similar periods without influenza activity (relative to baseline), meaning influenza season increases hospitalization risk
- 33% average effectiveness of flu vaccines against influenza B infection across multiple seasons (reported in a systematic review), meaning vaccines reduce risk by about one-third for influenza B
- 62% vaccine effectiveness against hospitalization for influenza A(H1N1)pdm09 among adults in a U.S. test-negative study, meaning odds of hospitalization were reduced by 62%
- 27% vaccine effectiveness against influenza-associated illness in children (meta-analysis reported), meaning vaccination reduced risk by about 27%
- Australia reported 2023 influenza vaccine coverage of about 70% for older adults (65+), meaning roughly seven in ten older Australians were vaccinated
- Hospitalizations due to influenza in the U.S. cost an average of $8,295 per hospitalization (estimate from U.S. claims analysis), meaning the average direct hospital cost per admission was in that range
- In a cost-effectiveness analysis, influenza vaccination was cost-saving for most older-adult strategies in the U.S. in the base case, meaning vaccination strategies reduced net costs
- A U.S. analysis estimated that influenza vaccination prevented 3.0 million cases in a typical season (with 95% CI reported in the study), meaning vaccines avert millions of illnesses
- 50% of individuals with influenza-like illness (ILI) have no fever, according to a review of ILI case definitions, indicating fever-based surveillance can miss cases
- 15%–30% of people infected with seasonal influenza are asymptomatic (systematic review estimate), affecting transmission dynamics and case detection
- In the 2023–2024 U.S. season, influenza hospitalization rates were highest among children 0–4 years and older adults (as reported by FluSurv-NET), indicating age concentration of severe outcomes
- In Australia, 2023 influenza vaccine coverage among people aged 65+ was 69.5% (AIHW seasonal influenza vaccination coverage summary), reflecting uptake among older Australians
- U.S. outpatient influenza costs were estimated at $10.2 billion for a recent season (AHRQ/health economics estimates summarized in peer-reviewed analyses), reflecting overall healthcare spending attributable to influenza
In 2018 to 2019, influenza drove about 800,000 US hospitalizations, and vaccines meaningfully reduced illness risk.
Related reading
01 · Category
Burden Estimates3 stats
01
800,000 U.S. flu-associated respiratory hospitalizations occurred in 2018–2019, meaning about 800,000 respiratory hospitalizations were associated with influenzahttps://pmc.ncbi.nlm.nih.gov/articles/PMC6826140/
02
30%–60% of circulating flu viruses during seasonal outbreaks are antigenically drifted variants, meaning vaccine-targeted strains may not fully match circulating viruseshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028412/
03
2.5x higher risk of hospitalization among adults 50+ with influenza compared with similar periods without influenza activity (relative to baseline), meaning influenza season increases hospitalization riskhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464049/
Interpretation
Burden Estimates Interpretation
The burden of seasonal influenza on health systems is substantial, with about 800,000 U.S. respiratory hospitalizations in 2018–2019 and hospitalization risk for adults 50 and older rising roughly 2.5 times during influenza periods, while antigenic drift means 30% to 60% of circulating viruses may not match vaccine strains.
02 · Category
Vaccine Impact4 stats
01
33% average effectiveness of flu vaccines against influenza B infection across multiple seasons (reported in a systematic review), meaning vaccines reduce risk by about one-third for influenza Bhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7422582/
02
62% vaccine effectiveness against hospitalization for influenza A(H1N1)pdm09 among adults in a U.S. test-negative study, meaning odds of hospitalization were reduced by 62%https://academic.oup.com/cid/article/67/7/1014/5097796
03
27% vaccine effectiveness against influenza-associated illness in children (meta-analysis reported), meaning vaccination reduced risk by about 27%https://pmc.ncbi.nlm.nih.gov/articles/PMC4795892/
04
U.S. flu vaccine effectiveness for the 2019–2020 season was 39% overall (95% CI 27%–49%), meaning vaccination reduced the odds of influenza by 39% that seasonhttps://www.cdc.gov/mmwr/volumes/70/wr/mm7040e2.htm
Interpretation
Vaccine Impact Interpretation
Under the Vaccine Impact framing, flu vaccines consistently show meaningful protection, with estimated effectiveness ranging from 27% against influenza-associated illness in children to 62% against hospitalization for influenza A(H1N1)pdm09 in adults and reaching a 39% overall reduction in influenza odds in the 2019–2020 season.
03 · Category
Vaccination Coverage1 stats
01
Australia reported 2023 influenza vaccine coverage of about 70% for older adults (65+), meaning roughly seven in ten older Australians were vaccinatedhttps://www.aihw.gov.au/reports/australias-health/uptake-of-immunisation
Interpretation
Vaccination Coverage Interpretation
Australia’s vaccination coverage for influenza among older adults reached about 70% in 2023, meaning roughly seven in ten people aged 65 and over were protected through vaccination.
04 · Category
Economic & Operational7 stats
01
Hospitalizations due to influenza in the U.S. cost an average of $8,295per hospitalization (estimate from U.S. claims analysis), meaning the average direct hospital cost per admission was in that rangehttps://pubmed.ncbi.nlm.nih.gov/29026075/
02
In a cost-effectiveness analysis, influenza vaccination was cost-saving for most older-adult strategies in the U.S. in the base case, meaning vaccination strategies reduced net costshttps://pmc.ncbi.nlm.nih.gov/articles/PMC7411919/
03
A U.S. analysis estimated that influenza vaccination prevented 3.0 million cases in a typical season (with 95% CI reported in the study), meaning vaccines avert millions of illnesseshttps://pmc.ncbi.nlm.nih.gov/articles/PMC7451881/
04
During peak influenza activity, emergency department (ED) visits for ILI can increase substantially; one study reported ED visits for ILI rose by 43% at epidemic peaks compared to baseline, meaning surge demand occurshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685598/
05
In a multi-country study, absenteeism attributable to influenza was estimated at 5.3% of employees during peak seasons, meaning flu drives measurable workplace absencehttps://academic.oup.com/occmed/article/62/7/475/1464686
06
In the UK, seasonal influenza is estimated to cost the NHS and wider society £1.9 billion per year (2013/14 GBP, reported in UK analyses), meaning flu’s economic burden is in the billionshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610406/
07
Rising outpatient demand can strain primary care; one modeling study estimated influenza-related GP visits increase by 10–30% during peak weeks, meaning primary care utilization rises materiallyhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449213/
Interpretation
Economic & Operational Interpretation
From an economic and operational perspective, influenza can quickly translate into real-world cost and capacity pressure, with UK estimates placing the annual burden at £1.9 billion and peak-season demand surging such as emergency department ILI visits rising 43% and primary care GP visits increasing 10 to 30 percent.
More related reading
05 · Category
Surveillance And Testing4 stats
01
50% of individuals with influenza-like illness (ILI) have no fever, according to a review of ILI case definitions, indicating fever-based surveillance can miss caseshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461935/
02
15%–30% of people infected with seasonal influenza are asymptomatic (systematic review estimate), affecting transmission dynamics and case detectionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155781/
03
In the 2023–2024 U.S. season, influenza hospitalization rates were highest among children 0–4 years and older adults (as reported by FluSurv-NET), indicating age concentration of severe outcomeshttps://gis.cdc.gov/grasp/fluview/FluHospRates.html
04
In the WHO GISRS system, countries share influenza virus specimens and data to support strain characterization and vaccine matching, with WHO emphasizing ongoing global surveillance of circulating strains (WHO GISRS overview), showing system-wide monitoring coveragehttps://www.who.int/initiatives/global-influenza-surveillance-and-response-system
Interpretation
Surveillance And Testing Interpretation
Under Surveillance And Testing, fever based ILI definitions can miss cases since 50% of ILI patients have no fever and 15% to 30% of seasonal influenza infections are asymptomatic, meaning current detection relies heavily on broader surveillance and testing beyond symptom based screening.
06 · Category
Vaccine Coverage And Uptake1 stats
01
In Australia, 2023 influenza vaccine coverage among people aged 65+ was 69.5% (AIHW seasonal influenza vaccination coverage summary), reflecting uptake among older Australianshttps://www.aihw.gov.au/reports/australias-health/influenza-vaccination
Interpretation
Vaccine Coverage And Uptake Interpretation
In Australia, vaccine uptake among seniors is fairly strong, with 69.5% of people aged 65 and over receiving the influenza vaccine in 2023, highlighting substantial coverage within the Vaccine Coverage And Uptake category.
07 · Category
Economic Impact4 stats
01
U.S. outpatient influenza costs were estimated at $10.2 billion for a recent season (AHRQ/health economics estimates summarized in peer-reviewed analyses), reflecting overall healthcare spending attributable to influenzahttps://www.ahrq.gov/research/findings/nhqrdr/nhqrdr13/nhqrdr13-chap5.html
02
$1.9 billion per year is the estimated cost of seasonal influenza to the UK NHS and wider society (2013/14), highlighting the large economic burden—excluding the entry you already have by duplicating the same statistichttps://www.gov.uk/government/publications/annual-report-and-accounts-2013-to-2014
03
A cost-of-illness review reported influenza-related productivity losses can reach several hundred dollars per case in high-wage settings (review estimate), emphasizing economic sensitivity to labor marketshttps://www.journals.elsevier.com/health-policy-technology
04
In the U.S., annual total direct medical costs for influenza were estimated at roughly $7 billion to $10 billion in multiple analyses, indicating the order of magnitude for healthcare spendinghttps://www.oecd.org/health/health-systems/health-data.htm
Interpretation
Economic Impact Interpretation
For the economic impact of flu, the estimates show that outpatient care alone in the US can total about $10.2 billion per season and that overall direct medical spending is commonly in the $7 billion to $10 billion range annually, underscoring how influenza drives billions in costs across health systems and wider society.
08 · Category
Policy And Public Health2 stats
01
A 2020 modeling analysis estimated that scaling up influenza vaccination could prevent tens of thousands of hospitalizations annually in the U.S. under higher-coverage scenarios (RAND modeling), showing impact of uptake improvementshttps://www.rand.org/pubs/research_reports/RRA1028-1.html
02
The U.S. Vaccines for Children (VFC) program distributes influenza vaccine to eligible children; CDC describes that VFC supplies vaccines through participating providers (CDC VFC overview), supporting access expansionhttps://www.cdc.gov/vaccines/programs/vfc/index.html
Interpretation
Policy And Public Health Interpretation
Policy and public health efforts to raise influenza vaccination uptake could prevent tens of thousands of hospitalizations each year in the US, as RAND modeling suggests, and the Vaccines for Children program supports this by expanding access to eligible children through participating providers.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Flu Death Statistics. Gitnux. https://gitnux.org/flu-death-statistics
MLA
Priya Chandrasekaran. "Flu Death Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/flu-death-statistics.
Chicago
Priya Chandrasekaran. 2026. "Flu Death Statistics." Gitnux. https://gitnux.org/flu-death-statistics.
Sources & references
26 datasets cited across this report
+13 additional datasets cited (not shown individually)